American food And the drug administration has just approved only Lenacapavir, which is an injective form of HIV prevention, which is about 100 % efficient and requires only two doses each year. Science The magazine described the medicine as the most important scientific advance of 2024.
In clinical trials, Lenkapware proved to be 99.9 % effective for preventing HIV infection through sexual transmission in people weighing more than 35kg. Drugs, an antibacterial, works not through the stimulation of immune response, but also prevents HIV from reproduction during its early stages – in particular, disrupting the virus’s capsed protein function. This happens until the body receives injection every six months.
Lencopeware has already been approved as HIV treatment in some countries, which contains virus forms that are resistant to other treatment. However, before this week, its profile use was not approved anywhere, which made the FDA’s decision an important new development in the fight against the HIV/AIDS epidemic.
Drugs are not the first drug that can be taken prematurely to prevent HIV infection: Previous Exhibition Profilexes (PEP) tablets were already available in several countries, including the United States. But they should be taken every day, and to ensure the ongoing access to these medicines, and that people really remember taking them, this is a famous challenge. It is hoped that the lasting effects of Lenkapvers will make people safe from the virus.
According to its creator, Gilad Sciences, Lenkapveer, will be marketed under the commercial name Yatgo. The company has pledged to produce 10 million dose by 2026.
In a statement on Wednesday, “This is a historic day of the fight against HIV for decades. Yazato is the most important scientific development of our time and offers a very real opportunity to help eliminate the HIV epidemic.”
However, access to the price of Lenkapvers may be interrupted. The annual list of Yazatgo will cost $ 28,218 per person in the United States. The executive director of the Joint United Nations Program, Executive Director of HIV/AIDS (UNEDS), Vinnie Binema, has also flagged the past that the drug is unbearable for many people in Africa, where the drug has the most effective impact. Almost two -thirds of people living with HIV around the world live in Sahara Africa.
Gilad said in a statement last year that she was developing a strategy to enable the Lenkapveer to enable global, sustainable access, although the company has not yet provided detailed information about how it will do it. An option can be “voluntary licensing”, where other companies are allowed to produce and sell a general version of patented products that provide people in some (often low -income) countries. Researchers at the University of Liverpool in the UK have calculated that a one -year price can be made available for at least $ 25.
This story originally appeared Wired Nspol And it has been translated from Spanish.
